Status:
UNKNOWN
Relationship Between Standard Treatment Efficacy and The Tumor Microenvironment in Advanced Gastric Cancer
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Gastric Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Gastric cancer is among the most common malignant tumors nationwide with high morbidity and mortality. Attributing to its insidious onset and rapid progress, 70% of patients with gastric cancer were i...
Detailed Description
Gastric cancer is among the most common malignant tumors nationwide with high morbidity and mortality. Attributing to its insidious onset and rapid progress, 70% of patients with gastric cancer were i...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed advanced gastric cancer.
- Willing to receive anti-tumor drug treatment.
- Willing to provide residual tumor tissues after routine clinical diagnosis for tumor microenvironment detection analysis.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
- At least one measurable lesion or non-measurable but evaluable as defined by RECIST 1.1.
Exclusion
- 1\. Human epidermal growth factor receptor 2 (HER2) is positive, that is, tissue immunohistochemical staining (IHC) (3+) or IHC (2+), and tissue fluorescence in situ hybridization (FISH) is positive.
Key Trial Info
Start Date :
April 27 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2023
Estimated Enrollment :
89 Patients enrolled
Trial Details
Trial ID
NCT04850716
Start Date
April 27 2021
End Date
November 1 2023
Last Update
March 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510515